Innate Pharma announces revenue for the first nine months of 2012 and updates on its cash position

• Revenue of 8.0 million euros
• Cash position as at September 30, 2012 of 32.3 million euros
• Change to the supervisory board

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue of 8.0 million euros for the first nine months of 2012, compared with 3.1 million euros for the same period in 2011. During the first nine months of 2012, this revenue resulted from Innate Pharma’s collaboration and licensing agreement with Bristol-Myers Squibb, signed in July 2011.

Cash, cash equivalents and current financial instruments of the Company amounted to 32.3 million euros at September 30, 2012.